|
May 14
|
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
|
|
May 13
|
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
|
|
Mar 11
|
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
|